Related Experiment Video
Updated: Oct 25, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Inflammation Alters Relationship Between High-Density Lipoprotein Cholesterol and Cardiovascular Risk in Patients
Jae Young Kim1,2, Jung Tak Park1, Hyung Woo Kim1
1Department of Internal Medicine College of Medicine Institute of Kidney Disease Research Yonsei University Seoul Korea.
Insights
Inflammation alters the relationship between high-density lipoprotein cholesterol (HDL-C) and cardiovascular risk in chronic kidney disease patients. Higher HDL-C may be protective without inflammation, but associated with increased risk when inflammation is present.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Clinical Chemistry
Background:
- High-density lipoprotein (HDL) function can shift from protective to proatherosclerotic during inflammation.
- Understanding HDL's role in chronic kidney disease (CKD) is crucial due to increased cardiovascular risk in this population.
Purpose of the Study:
- To investigate how inflammation modifies the association between HDL cholesterol (HDL-C) levels and adverse cardiovascular outcomes in patients with CKD.
Main Methods:
- Prospective cohort study (KNOW-CKD) including 1864 CKD patients.
- HDL-C levels and hs-CRP (high-sensitivity C-reactive protein) for inflammation (≥1.0 mg/L) were assessed.
- Extended major adverse cardiovascular events (MACE) were the primary outcome, analyzed using multivariable Cox regression.
Main Results:
- No overall association between HDL-C and MACE was found in the entire cohort.
- A significant interaction between inflammation and HDL-C on MACE risk was observed (P=0.003).
- In non-inflamed patients, higher HDL-C showed a trend towards lower risk (not significant after correction); in inflamed patients, higher HDL-C showed a trend towards increased risk.
Conclusions:
- The association between HDL-C and cardiovascular outcomes in CKD patients is dependent on inflammatory status.
- Inflammation may reverse the potentially protective role of HDL-C, indicating a need for tailored risk assessment in CKD.
Abstract:
Background The function of high-density lipoprotein can change from protective to proatherosclerotic under inflammatory conditions. Herein, we studied whether inflammation could modify the relationship between high-density lipoprotein level and risk of adverse outcomes in patients with chronic kidney disease . Methods and Results In total, 1864 patients from the prospective KNOW-CKD (Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease) were enrolled. The main predictor was high-density lipoprotein cholesterol (HDL-C) level. Presence of inflammation was defined by hs-CRP (high-sensitivity C-reactive protein) level of ≥1.0 mg/L. The primary outcome was extended major adverse cardiovascular events. During 9231.2 person-years of follow-up, overall incidence of the primary outcome was 15.8 per 1000 person-years. In multivariable Cox analysis after adjusting for confounders, HDL-C level was not associated with the primary outcome. There was a significant interaction between the inflammatory status and HDL-C for risk of extended major adverse cardiovascular events (P=0.003). In patients without inflammation, the hazard ratios (HRs) (95% CIs) for HDL-C levels <40, 50 to 59, and ≥60 mg/dL were 1.10 (0.50-1.82), 0.95 (0.50-1.82), and 0.42 (0.19-0.95), respectively, compared with HDL-C of 40 to 49 mg/dL. However, the significant association for HDL-C ≥60 mg/dL was not seen after Bonferroni correction. In patients with inflammation, we observed a trend toward increased risk of extended major adverse cardiovascular events in higher HDL-C groups (HRs [95% CIs], 0.73 [0.37-1.43], 1.24 [0.59-2.61], and 1.56 [0.71-3.45], respectively), but without statistical significance. Conclusions The association between HDL-C level and adverse cardiovascular outcomes showed reverse trends based on inflammation status in Korean patients with chronic kidney disease. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT01630486.
More Related Videos
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
09:15Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Inflammation